Sentences with phrase «stable disease»

An analysis of the pancreatic cancer patients in the trial showed no responses to the combination therapy, with a disease control rate of 33 % (five patients with stable disease).

The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months.

Diabetes and hypertension can be held at a safe, manageable level precisely because they are essentially stable diseases.

In melanoma, researchers observed prolonged stable disease in 20 percent of the patients on temozolomide.

«Encouraging» period of stable disease suggested in direct injection vaccine treatment of pancreatic cancer.»

What's more, one patient who had failed multiple prior treatments for renal cell carcinoma had a confirmed durable partial response and two patients with colorectal cancer had prolonged stable disease.

In cohort two, which had patients that were heavily pretreated, six patients had a partial response, and six achieved stable disease for at least six months, for a combined disease control rate of 54.5 percent.

While in another trial, researchers observed stable disease in 75 percent of patients with metastatic melanoma on temsirolimus.

All six patients showed stable disease on imaging (per RECIST criteria) at one month after treatment.

During the study, 15 patients had at least one imaging scan to retest the extent and location of their cancers — with 12 patients experiencing stable disease — for more than the four - month period, on average, and one patient experiencing a partial response to the treatment (measured as at least a 30 percent reduction in the size of the tumors.)

When examined alone, the ASPS patients had a clinical benefit rate of 83 %, as two patients had stable disease along with the three partial responses.

Of the 30 evaluable patients, 1 patient achieved a complete response, 1 had a partial response, and 6 patients had stable disease by immune - related response criteria.

Immune - related stable disease is a measure of effectiveness used in cancer immunotherapy clinical trials.

This could greatly expand the utility of hair restoration surgery to women and to younger patients — now it is largely restricted to the treatment of male - pattern baldness in patients with stable disease.»

Of 22 patients evaluable for response, 3 (14 percent) had very good partial responses, 3 (14 percent) had minor responses, and 10 (45 percent) had a period of stable disease.

In cohort one, 10 patients had a partial response to vemurafenib, and an additional nine achieved stable disease for at least six months, for a combined disease control rate of 73 percent.

Of these patients, 1 achieved a durable complete response (95 weeks), 1 achieved a durable partial response (53 weeks), 1 had a transient partial response, and 3 had stable disease at the conclusion of the trial.

Of these nine patients, 100 percent either had stable disease or had a partial response to the treatment used in this study.

Of the 21 patients treated, nine previously either had stable disease or responded to single - agent immunotherapy before becoming resistant to this treatment.

«We can reassert control, at least in terms of stable disease, in essentially everybody we've treated so far,» Wrangle said.

patients had partial response and 35 % had stable disease, for an overall 94 % disease control rate.

Among 26 participants in this dose - escalation study, eight patients had stable disease for more than six weeks following treatment with entolimod, and three patients maintained disease stability for longer than 12 weeks.

Fourteen people had near complete responses, while two had a very good partial response, two had a partial response, one had stable disease, and one had progressive disease.

Overall, 65.2 % of patients on regorafenib showed complete or partial response or stable disease, compared to 36.1 % of the placebo group.

Four patients had stable disease, nine patients had progressive disease, and three were not evaluable for response.

The disease control rate (defined as partial response or stable disease for more than 12 weeks) for all patients was 32 percent (6 of the 19 patients) and 50 percent (three of six patients) in patients who received one prior line of chemotherapy.

Of the 19 pancreatic patients, one had a complete response and two had partial responses, while four patients had stable disease.

Research from Rutgers Cancer Institute of New Jersey shows that the «first in human» series of vaccine injections given directly into a pancreatic cancer tumor is not only well tolerated, but also suggests an «encouraging» period of stable disease.

One of these patients has stable disease and the other has a durable confirmed partial response.

Data from the trial on 29 patients presented in June of this year showed that 24 % of the patients achieved a partial response, 14 % a minimal response, and another 24 % had stable disease.

Those patients who achieved a complete or partial response or stable disease could get an additional eight infusions every 4 weeks.

[18] Recent phase I data on osimertinib, 160 mg / d, in leptomeningeal disease of EGFR - mutant NSCLC (ClinicalTrials.gov identifier: NCT02228369) showed that 23 of 32 patients who underwent brain image assessment 12 weeks after initiation of treatment with osimertinib showed improvement: radiologic improvement in 10 patients and stable disease in 13 patients, and with 9 of the 23 patients demonstrating improvement in neurologic symptoms.

Five patients in the «other sarcomas» cohort had stable disease (29.4 %).

There were five partial responses across the six cohorts (10.4 %), and 15 patients had stable disease (31.3 %); this yielded a clinical benefit rate of 41.7 %.

Within the mucosal melanoma subgroup, there were 8 partial responses (23 %) and 7 patients with stable disease (20 %), but no complete responses were observed.

Another 13 % had stable disease, 9 % had progressive disease, and 4 % could not be evaluated.

Of 16 patients enrolled in the trial, four had a partial response, one had stable disease, and six continued to have progressive disease, the work showed.

Within the subset of 23 patients that were in the higher dose cohorts and would qualify for the Toca 5 trial, patients had a median survival of 14.4 months and 43.5 % (10/23) of patients had clinical benefit (5 complete responses and 5 stable disease patients).

nine patients, 100 percent either had stable disease or had a partial response to the treatment used in this study.

[10] Complete responses (CRs) and partial responses (PRs) were reported in 3.2 % and 8.7 % of patients, respectively, with stable disease (SD) in 25 % of the two patient cohorts combined.

The degree of ketosis depends on the partial remission and a stable disease, but there is no lack in calories and no weight loss.

Of even more interest, dogs receiving vinblastine and piroxicam together had the following tumor responses: 58 % partial remission, 33 % stable disease, and 8 % progressive disease with a median survival of 299 days (range 21 - 637 days).

The first finding was that the antitumor effects were encouraging, consisting of partial remission in 5 dogs and stable disease in 7 dogs.